NewLeaf Symbiotics raises $30 million to convert unique biologics into agriculture products


In Missouri, NewLeaf Symbiotics completed the second close of its $30 million series C financing, accelerating plans to convert proven applications of its unique biologicals platform into products for large-scale agriculture. S2G Ventures joined first close lead investors Monsanto Growth Ventures and Otter Capital to finalize the oversubscribed financing.

“We invest in transformative agriculture companies whose technologies and products are driving the sustainability revolution and can better align the food system to meet consumer demands,” said S2G CIO and Managing Director Sanjeev Krishnan. “We’ve been following NewLeaf for several years and have witnessed how the company’s innovative strategy has created a product pipeline that can move the needle in Ag biologicals.”

NewLeaf will use the invested capital to commercialize seed treatment and in-furrow products for soybeans, corn, wheat, peanuts, and other crops. The company is tripling its R&D and pilot production square footage and is expanding its Prescriptive Biologics Knowledgebase.